Skip to main content
Premium Trial:

Request an Annual Quote

Trinean Licenses Microfluidic IP from PerkinElmer's Caliper Business

NEW YORK (GenomeWeb News) – Belgian spectrophotometer firm Trinean today said it has licensed intellectual property covering microfluidic technologies from PerkinElmer's Caliper Life Sciences business directed at UV-VIS quantification analysis.

The license allows Trinean to design and develop microfluidic cartridges and instruments for the UV/VIS quantification of light-absorbing substances for certain life science applications, Trinean said. Further details of the deal were not disclosed.

"The combined IP from Trinean and PerkinElmer will boost the expansion of our platform for DNA, RNA, and protein quantification and quality control," Philippe Stas, CEO of Trinean, said in a statement.

"The use of microfluidics for UV/Vis spectrometry is an exciting market development,"
Kevin Hrusovsky, life sciences president for PerkinElmer, added. "We continue to leverage our microfluidics portfolio through licensing collaborations such as our agreement with Trinean to extend our market reach and create additional revenue opportunities."

Caliper and Trinean inked a deal two years ago giving Caliper exclusive rights to distribute the Belgian company's automated UV/Vis spectral analysis platform in North America.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.